Last reviewed · How we verify
NCT05016024
Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.
NA trial testing Colilen IBS in Irritable Bowel Syndrome in 71 participants. Completed in 15 February 2023.
15 February 2023
Quick facts
| Lead sponsor | Aboca Spa Societa' Agricola |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 71 |
| Start date | 5 August 2021 |
| Primary completion | 15 February 2023 |
| Estimated completion | 15 February 2023 |
| Sites | 7 locations across Italy, Germany |
Drugs / interventions tested
- Colilen IBS
- Placebo
Conditions studied
- Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
Sponsor
Aboca Spa Societa' Agricola — full company profile →
Who can join
Adults 18 to 75, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aimed to investigate the efficacy and safety of Colilen IBS, a Medical Device made of natural substances, even when taken in addition to other therapies, for the treatment of Irritable Bowel Syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05016024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Irritable Bowel Syndrome
Currently open trials in the same condition.
- NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
- NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting
Other Aboca Spa Societa' Agricola trials
Trials by the same sponsor.
- NCT05904938 — Oral Administration of Actitan-F in Paediatric Diarrhoea · NA · unknown
- NCT05192317 — Administration of a Natural Molecular Complex in Functional Chronic Constipation · NA · unknown
- NCT03531372 — Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn. · NA · completed
- NCT03545724 — Effectiveness & Safety of Neofitoroid® in Hemorrhoidal Disease · NA · completed
- NCT03581929 — Efficacy of MEMORMAX in Subjects With MCI · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05016024 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aboca Spa Societa' Agricola
- Last refreshed: 16 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05016024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing